INFORS HT Opens New Offices in the US

INFORS HT, a global leader in the production of shakers, bioreactors and bioprocess control software, opened new offices in the US.
INFORS HT has, until now, been represented in the US by ATR (Appropriate Technical Resources Inc.). From 1 January 1 2014, INFORS HT is going to take over this part of the ATR business — including its infrastructure, the existing customer relations, and full complement of staff.
To guarantee a seamless continuity of service to their customers, all sales and service offices as well as production teams will remain unchanged, as will any current contact personnel. By increasing its presence in the US, INFORS HT will not only expand its customer base but give its customers direct day-to-day contact with INFORS HT representatives and no longer via a third party.
Marcel Brauchli, CEO of INFORS HT, points out: “We’re proud of our new branches and look forward to having direct contact with our customers in the USA. We’re convinced that, in this way, we can improve customer relations and build more successful long term partnerships.”
This new direct contact will also bring about an added value to customers. They will have access to a committed team who have a wealth of experience, technical know-how and innovative thinking that is second-to-none.
The new CEO of Infors US Inc., Simon Egli, holds a master degree in biotechnology engineering from the University of Waedenswil (CH). Before joining INFORS HT at the headquarters in Switzerland, he worked in various bioprocess production and validation positions at a management level. He has been with INFORS HT for 3 years.
Related News
-
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News 3 ways ChatGPT will impact pharma marketing teams
What does the rise of AI-powered chatbots such as ChatGPT and GPT-4 mean for pharma marketeers? -
News Eli Lilly, Novo Nordisk, and Sanofi cut insulin prices by up to 78%
Insulin prices have dropped in a stark play by the three biggest makers of the product, after calls from the top of the US government. -
News Open letter challenges EU Commission on medicine supply chain
In an open letter to the European Commission, Medicines for Europe calls for a new medicine security contract with their goal to improve access to medicine and ensure a secure supply chain to Europe.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance